Skip to main content
EJNMMI Research

Table 4 ROC analyses of PET-parameters in predicting axillary response following NST in HER2-positive/TN breast cancer patients

From: Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype

 

AUC

Cut-off

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

All HER2-positive/TN breast cancer patients

LN–SUVmax

0.82 (0.67–0.98)

4.89

90 (54–99)

69 (48–85)

53 (29–76)

95 (72–100)

LN–SUVmean

0.83 (0.67–99)

3.77

90 (54–99)

81 (60–93)

64 (36–86)

96 (75–100)

Clinically node-positive HER2-positive/TN breast cancer patients

LN–SUVmax

0.74 (0.53–0.95)

7.07

70 (35–92)

82 (56–95)

70 (35–92)

82 (56–95)

LN–SUVmean

0.75 (0.54–0.96)

3.77

90 (54–99)

71 (44–89)

64 (36–71)

92 (62–100)

  1. AUC, area under the curve; HER2, human epidermal growth factor 2 receptor; LN, lymph node; NPV, negative predictive value; PPV, positive predictive value; SUV, standardized uptake value; TN, triple negative
Back to article page